Immatics N.V.
NASDAQ:IMTXBiotechnology
+$0.15 today
- Market cap
- $912.78M
- Beta
- 1.30
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$1.59
Volume 1.57M
Average 0.46M
IMTX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Immatics N.V.NASDAQ: IMTX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of €2.82M fell 10.2% year over year, behind the -2.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 10.2% from the prior quarter. Over 3 fiscal years it compounded at +19.6% a year.
Context
- Depreciation & amortization amounted to 24.7% of revenue in FY2025, up 16.8 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -10.2% toward the trailing-twelve-month pace of -2.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
EUR · from the cash flow
- Latest · FY2025
- 11.91M EUR
- Year-over-year change
- -2.6%
- 4-year CAGR
- +22.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.91M | -2.6% |
| FY2024 | 2024-12-31 | 12.23M | +69.0% |
| FY2023 | 2023-12-31 | 7.23M | +3.8% |
| FY2022 | 2022-12-31 | 6.97M | +32.5% |
| FY2021 | 2021-12-31 | 5.26M | — |
Depreciation & Amortization vs competitors
How IMTX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -2.4% is the 3rd highest of 11, against a peer median of -12.5%.
- Depreciation & amortization amounts to 32.3% of revenue for IMTX, versus a peer median of 9.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €676.85M EUR | +122.9% | +43.9% | 25.6% | |
| LTM Sep 2026 | $50.27M USD | +111.9% | +16.3% | 3.7% | |
| LTM Mar 2026 | $19.68M USD | -2.6% | +3.0% | 28.9% | |
| LTM Mar 2026 | $12.13M USD | -8.0% | -4.7% | — | |
| LTM Mar 2026 | €12.05M EUR | -2.4% | +19.6% | 32.3% | |
| LTM Mar 2026 | $10.43M USD | -42.2% | -11.2% | 33645.2% | |
| LTM Mar 2026 | $3.36M USD | -17.0% | -23.1% | 0.9% | |
| LTM Mar 2026 | $2.88M USD | -18.4% | -17.7% | 31.5% | |
| LTM Mar 2026 | $2.69M USD | -30.3% | -32.6% | 6.0% | |
| LTM Mar 2026 | $1.98M USD | -3.3% | +34.1% | 9.2% | |
| LTM Mar 2026 | $175K USD | -96.8% | -25.1% | 0.8% | |
| Peer median (excluding IMTX) | — | -12.5% | -8.0% | 9.2% | |
Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (93.34M) | 37.51M | (94.65M) | 15.22M | (188.69M) |
| Depreciation & Amortization | 5.26M | 6.97M | 7.23M | 12.23M | 11.91M |
| Deferred Income Tax | 11.15M | 4.52M | 0 | 6.13M | 0 |
| Stock-Based Compensation | 26.4M | 22.57M | 20.71M | 17.64M | 0 |
| Change in Working Capital | (31.7M) | 37.26M | 81.63M | (163.88M) | (42.23M) |
| Accounts Receivables | 569K | (429K) | (2.98M) | (1.76M) | (232.45K) |
| Inventory | 0 | 0 | (84.24M) | 0 | 0 |
| Accounts Payables | (31.78M) | 45.56M | 84.24M | 0 | (36.13M) |
| Other Working Capital | (483K) | (7.87M) | 84.61M | (162.11M) | (5.87M) |
| Other Non-Cash Items | 433K | (8.7M) | 3.31M | (45.37M) | 49.36M |
| Operating Cash Flow | (81.78M) | 100.13M | 18.23M | (158.03M) | (169.66M) |
| Capital Expenditures | (5.66M) | (6.22M) | (30.96M) | (16.48M) | (6.3M) |
| Acquisitions (Net) | 551K | (199.91M) | 0 | 0 | 0 |
| Purchases of Investments | (11.3M) | (216.32M) | (415.33M) | (450.35M) | (324.92M) |
| Sales of Investments | 24.45M | 12.7M | 414.74M | 314.44M | 528.16M |
| Other Investing Activities | (551K) | 199.96M | (8K) | (206K) | 0 |
| Investing Cash Flow | 7.49M | (209.79M) | (31.39M) | (152.39M) | 196.7M |
| Debt Repayment | (2.71M) | (2.84M) | (3.85M) | (2.01M) | 0 |
| Common Stock Issued | 94K | 134.48M | 90.4M | 343.01M | 96.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (7.93M) | (2.04M) | (21.31M) | (2.84M) |
| Financing Cash Flow | (2.61M) | 123.71M | 84.52M | 319.68M | 93.51M |
| Effect of Forex Changes | 2.37M | 1.48M | (1.4M) | 9.01M | 16.56M |
| Net Change in Cash | (74.54M) | 15.53M | 69.95M | 18.28M | 137.12M |
| Free Cash Flow | (87.44M) | 93.92M | (12.73M) | (174.51M) | (175.95M) |
Immatics N.V.
NASDAQ:IMTX
Intrinsic Alpha fair value
Locked
Current Price
$6.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.